Chemical compounds

Retinal Consultants of Arizona Partners With American Vision Partners

Retrieved on: 
Tuesday, September 10, 2019
Chemical compounds, ARIZONA, Retinal, Organic compounds, Branches of biology

The affiliation with Retinal Consultants of Arizona represents the eighth partnership announced by American Vision Partners within the last 24 months.

Key Points: 
  • The affiliation with Retinal Consultants of Arizona represents the eighth partnership announced by American Vision Partners within the last 24 months.
  • To learn more about a partnership with American Vision Partners, please visit http://www.AmericanVisionPartners.com , or contact Andrew Hewlett at [email protected] .
  • American Vision Partners ("AVP") is one of the nation's largest and fastest growing eye care physician practice management organizations.
  • Retinal Consultants of Arizona ("RCA") was established in 1980 in Phoenix, Arizona.

Ulterion® Selected For The NextGen Consortium's Advanced Solutions Program

Retrieved on: 
Tuesday, September 10, 2019
Chemical compounds, Chemistry, Physical sciences, Coffee in Seattle, Starbucks, Iron(III) chloride, Nextgen, McDonald's

TAYLORS, South Carolina, Sept. 10, 2019 /PRNewswire/ -- Ulterion coatings from Jain Chem, Ltd. ofTaylors, South Carolinahas been selected as a participant in the NextGen Consortium's advanced solutions program to foster sustainable cup solutions for the food and beverage industry.

Key Points: 
  • TAYLORS, South Carolina, Sept. 10, 2019 /PRNewswire/ -- Ulterion coatings from Jain Chem, Ltd. ofTaylors, South Carolinahas been selected as a participant in the NextGen Consortium's advanced solutions program to foster sustainable cup solutions for the food and beverage industry.
  • The NextGen Consortium , a multi-year consortium of food and beverage service leaders, managed by Closed Loop Partners, with founding partners Starbucks and McDonald's, is searching for solutions that eliminate the entry of fiber-based cups into landfills.
  • "Jain Chem was selected to participate in the advanced solutions program because we recognized their importance in further developing the sustainable cup ecosystem," noted Daniel Liswood, Project Director of the NextGen Consortium at Closed Loop Partners.
  • Jain Chem adheres to the highest quality, safety and environmental standards and our manufacturing facility is ISO 9001:2015 certified.

Ulterion® Selected For The NextGen Consortium's Advanced Solutions Program

Retrieved on: 
Tuesday, September 10, 2019
Chemical compounds, Chemistry, Physical sciences, Coffee in Seattle, Starbucks, Iron(III) chloride, Nextgen, McDonald's

TAYLORS, S.C., Sept. 10, 2019 /PRNewswire/ -- Ulterion coatings from Jain Chem, Ltd. ofTaylors, South Carolinahas been selected as a participant in the NextGen Consortium's advanced solutions program to foster sustainable cup solutions for the food and beverage industry.

Key Points: 
  • TAYLORS, S.C., Sept. 10, 2019 /PRNewswire/ -- Ulterion coatings from Jain Chem, Ltd. ofTaylors, South Carolinahas been selected as a participant in the NextGen Consortium's advanced solutions program to foster sustainable cup solutions for the food and beverage industry.
  • The NextGen Consortium , a multi-year consortium of food and beverage service leaders, managed by Closed Loop Partners, with founding partners Starbucks and McDonald's, is searching for solutions that eliminate the entry of fiber-based cups into landfills.
  • "Jain Chem was selected to participate in the advanced solutions program because we recognized their importance in further developing the sustainable cup ecosystem," noted Daniel Liswood, Project Director of the NextGen Consortium at Closed Loop Partners.
  • Jain Chem adheres to the highest quality, safety and environmental standards and our manufacturing facility is ISO 9001:2015 certified.

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

Retrieved on: 
Tuesday, September 10, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Ureas, Cancer treatments, Pyridines, Angiogenesis inhibitors, Chloroarenes, Sorafenib, Tivozanib, Renal cell carcinoma, C-Met, TIVO-3, Tivozanib (FOTIVDA®), AVEO

AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial.

Key Points: 
  • AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial.
  • TIVO-3 is the Companys Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC).
  • These results include an OS hazard ratio (HR) below 1.00, favoring tivozanib (HR=0.99; 95% CI: 0.76-1.29; p=0.95).
  • An OS hazard ratio assesses the relative risk of death for the entirety of the data set.

Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer

Retrieved on: 
Tuesday, September 10, 2019
Chemical compounds, Organic compounds, Lung cancer, Quinazolines, Tyrosine kinase inhibitors, Tyrosine kinase receptors, Ethers, Osimertinib, Epidermal growth factor receptor, Non-small-cell lung carcinoma, T790M, Protein kinase inhibitor

The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).

Key Points: 
  • The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).
  • All 30 patients in the trial had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI) including 28 (93 percent) with osimertinib.
  • At the time of data cut-off on May 3, 2019, a total of 17 patients remained on treatment.
  • The global, phase 1, open label, two-part study is enrolling patients with metastatic or unresectable EGFR mutated NSCLC whose disease has progressed while taking an EGFR TKI.

Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer

Retrieved on: 
Tuesday, September 10, 2019
Chemical compounds, Organic compounds, Lung cancer, Quinazolines, Tyrosine kinase inhibitors, Tyrosine kinase receptors, Ethers, Osimertinib, Epidermal growth factor receptor, Non-small-cell lung carcinoma, T790M, Protein kinase inhibitor

The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).

Key Points: 
  • The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).
  • All 30 patients in the trial had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI) including 28 (93 percent) with osimertinib.
  • At the time of data cut-off on May 3, 2019, a total of 17 patients remained on treatment.
  • The global, phase 1, open label, two-part study is enrolling patients with metastatic or unresectable EGFR mutated NSCLC whose disease has progressed while taking an EGFR TKI.

Water Transportation Global Market Forecast To 2022

Retrieved on: 
Monday, September 9, 2019
Chemistry, Chemical compounds, Solvents, Eastern Canada, Great Lakes, Great Lakes region, Water, Maritime transport, Transport

NEW YORK, Sept. 9, 2019 /PRNewswire/ -- The water transportation market consists of sales of water transportation services by entities (organizations, sole traders and partnerships) that provide water transportation of passengers and cargo using watercraft, such as ships, barges, and boats.

Key Points: 
  • NEW YORK, Sept. 9, 2019 /PRNewswire/ -- The water transportation market consists of sales of water transportation services by entities (organizations, sole traders and partnerships) that provide water transportation of passengers and cargo using watercraft, such as ships, barges, and boats.
  • Water Transportation Global Market Forecast To 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global water transportation market.
  • It compares the water transportation market with other segments of the transportation services market by size and growth, historic and forecast.
  • Markets Covered: Deep Sea, Coastal, And Great Lakes, Inland Water Transportation Deep Sea Transportation, Coastal Transportation, Great Lakes Water Transportation , Inland Water Freight Transportation, Inland Water Passenger Transportation
    Companies Mentioned: A.P.

MicuRx Pharmaceuticals Reports Positive Top-Line Results From a US Phase 2 ABSSSI Clinical Trial of Novel Antibiotic Contezolid Acefosamil

Retrieved on: 
Monday, September 9, 2019
Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Health, Chemical compounds, Antibiotics, Hepatotoxins, Linezolid, Morpholines, RTT, Skin and skin structure infection, Pharmaceutical industry, Food and Drug Administration, Clinical trial, Brilacidin

MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2 randomized, double-blind clinical trial comparing contezolid acefosamil (MRX-4) with linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Key Points: 
  • MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2 randomized, double-blind clinical trial comparing contezolid acefosamil (MRX-4) with linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
  • We are very pleased with the excellent results of this study and plan to advance contezolid acefosamil into Phase 3 development next year, continued Dr. Yuan.
  • MicuRx plans Phase 3 clinical trials in ABSSSI and DFI in order to confirm the safety and efficacy profile of contezolid acefosamil, including with longer duration therapy.
  • Both contezolid and contezolid acefosamil have been granted QIDP designation and Fast Track status by the US FDA.

Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Retrieved on: 
Monday, September 9, 2019
Health, Articles, Chemical compounds, RTT, Lactams, PDE5 inhibitors, Psychiatric diagnosis, Female sexual arousal disorder, Food and Drug Administration, Sildenafil, Clinical trial

We look forward to meeting with the FDA later this year, and presenting the rigor that went into the study and the data collected.

Key Points: 
  • We look forward to meeting with the FDA later this year, and presenting the rigor that went into the study and the data collected.
  • Participants who met the eligibility criteria participated in one-on-one, in-depth interviews conducted by subject matter experts in the field of clinical outcome assessments and female sexual medicine.
  • Despite a number of approved prescription products for ED, no pharmacologic options have yet been approved by the FDA for FSAD.
  • If successful in clinical studies, Sildenafil Cream has the potential to be the first FDA-approved pharmacologic treatment option for FSAD.

Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

Retrieved on: 
Monday, September 9, 2019
Chemical compounds, Organic compounds, Amides, Piperazines, Lactams, Cyclacel, Breakthrough therapy, Genentech, Sapacitabine, 7+3, Olaparib, Chemotherapy regimen

We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

Key Points: 
  • We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
  • We look forward to reporting data from Part 2 and 3 of this study in 2020.
  • The DNA damage response program is evaluating an oral combination regimen of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS.
  • An IST is evaluating an oral combination regimen of sapacitabine and olaparib in patients with BRCA mutant breast cancer.